MEDICAL ADVOCATES
NEW AND NEWSWORTHY
Drug Archives

Back to New and Noteworthy

Files identified with this icon are in Portable Document Format (PDF) and
require the Adobe Acrobat Reader

Date

Drug

Citation

Jan 28/29	Tenofovir	Vitamin D3 Decreases Parathyroid Hormone in HIV-Infected Youth Being Treated With Tenofovir: A Randomized, Placebo-Controlled Trial.

Jan 27	Indinavir	Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin treated HIV/tuberculosis co-infected patients: a pilot study.

Jan 26	Lopinavir	Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.

Jan 25	Maraviroc Raltegravir	Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M-).

Jan 24	Raltegravir	Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing.

Jan 23	Darunavir	Efficacy and safety of once-daily ritonavir-boosted darunavir plus abacavir/lamivudine for treatment-naīve patients: A pilot study.

Jan 21/22	Maraviroc	Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.

Jan 20	Boceprevir (HCV Indications)	Phase III results of Boceprevir in treatment naīve patients with chronic hepatitis C genotype 1

Jan 19	Tenofovir	A novel LC-MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study.

Jan 18	Telaprevir (HCV Indications)	Telaprevir user's guide.

Jan 17	Tenofovir Abacavir	FULL-TEXT ARTICLE Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naīve Patients with HIV Infection.

Jan 16	Boceprevir (HCV Indications) Telaprevir (HCV Indications)	Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Jan 14/15	Zidovudine	Cycle arrest and aneuploidy induced by zidovudine in murine embryonic stem cells.

Jan 13	Sifuvirtide	Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor Sifuvirtide.

Jan 12	Rilpivirine	Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database.

Jan 11	Raltegravir	Mechanisms involved in CD4 gains in HIV-infected patients switched to raltegravir.

Jan 10	Tenofovir	Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings.

Jan 09	Etravirine	Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

Jan 07/08	Sorafenib (HIV/HBV Hepatocellular Carcinoma Indications)	Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.

Jan 06	Tipranavir	Tipranavir in the protease inhibitors arena.

Jan 05	Darunavir	Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1-Infected, Treatment-Naīve ARTEMIS Patients at Week 96.

Jan 04	HAART	Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications.

Jan 03	Elvitegravir Raltegravir	In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

Jan 02	Dolutegravir	Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor Dolutegravir.

Dec 31/ Jan 01	Raltegravir	Cost-effectiveness of raltegravir in HIV/AIDS.

Back to New and Noteworthy

Drug Update Archives